AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE (“CEE”)

Amryt, a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces the signing of a distribution agreement with Swixx BioPharma AG (“Swixx”) of Baar, Switzerland. 

Under the agreement, Amryt has appointed Swixx as exclusive distributor of  Myalepta® (metreleptin) in the EU territories of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia. In addition, Swixx will distribute Myalepta® for Amryt in the West Balkan countries of Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North Macedonia and Serbia.  These represent new territories for the Group providing scope to further accelerate revenue growth, augmenting the sales of Myalepta® already being generated through our existing salesforce in the EU.

Myalepta® was approved by the European Medicines Agency (“EMA”) in July 2018 as a treatment, in conjunction with diet, to treat the complications of leptin deficiency in patients with generalised and partial lipodystrophy.

Joe Wiley, CEO of Amryt Pharma, commented: “Metreleptin is currently the most significant driver of revenue growth for Amryt with sales growing 49% in Q1 2020 versus the same period in 2019. We are pleased to partner with Swixx, now the largest and fastest-growing dedicated agent for biopharma companies in CEE, as our distributor across these seventeen jurisdictions. Our partnership with Swixx will allow us to provide metreleptin to lipodystrophy patients in these new territories. We believe that the product is still relatively early in its growth trajectory and that this agreement will significantly accelerate our launch of metreleptin across the EMEA.”